Phase I study of intravenous PSC-833 and doxorubicin: Reversal of multidrug resistance

Japanese Journal of Cancer Research

Volumn 92, Issue 2, 2001, Pages 220-230

  Minami, Hironobu ^a   Ohtsu, Tomoko ^a   Fujii, Hirofumi ^a   Igarashi, Tadahiko ^a   Itoh, Kuniaki ^a   Uchiyama Kokubu, Noriko ^b   Aizawa, Tetsushi ^b   Watanabe, Torn ^b   Uda, Yoshinori ^b   Tanigawara, Yusuke ^c   Sasaki, Yasutsuna ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Doxurubicin; Multidrug resistance; Pharmacodynamics; Pharmacokinetics; PSC 833

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; GRANISETRON; VALSPODAR;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IN VITRO STUDY; LEUKOPENIA; MALE; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TUMOR CELLS, CULTURED;

EID: 0035084256     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01085.x     Document Type: Article

References (48)

1. Multiple-drug resistance in human cancer
2. Pharmacological considerations in the modulation of multidrug resistance
3. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
4. Expression of a multidrug-resistance gene in human tumors and tissues
5. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
6. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
7. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier
8. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
9. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers
10. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells
11. Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice
12. Modulation of multidrug-resistant multiple myeloma by cyclosporin
13. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate
14. Toremifen: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance
15. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
16. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma
17. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy
18. Modulation of vinblastine resistance with cyclosporine: A phase I study
19. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
20. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier
21. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
22. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
23. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
24. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
25. Parallel phase I study of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid Cancer and Leukemia Group B study 9420
26. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study
27. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A
28. Comparative studies on the pharmacokinetics between THP and adriamycin in the same patients
29. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein
30. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation
31. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport
32. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2
33. Combination of P-glycoprotein blockers, verapamil, PSC833, and Cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp)
34. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multi-specific organic anion transporter
35. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
36. Absence of the mdr1 a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin, A
37. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats
38. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
39. Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice
40. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
41. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833
42. Role of lipoprotein in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin
43. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
44. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo
45. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
46. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
47. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995)
48. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720)